Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results